NRG HN009

About this trial

The study has two parts: the first part of the study will help doctors determine if lowdose cisplatin given weekly is better tolerated by patients and has fewer side effects associated with the treatment. The second part of the trial will also help study doctors find out of if the low-dose cisplatin given weekly approach will extend your life by at least the same amount of time as the high-dose cisplatin given every three weeks approach. It is not yet possible to know if the low dose weekly cisplatin approach will cause fewer side effects or be as good at extending patients lives compared to the other usual approach using high-dose cisplatin.

Patient Profile

This study has 2 study groups. Both study groups receive the same treatment options. The group the patient will be in depends on the location of their head and neck cancer and if they have oropharynx cancer or cancer of unknown primary origin that is related to human papillomavirus (HPV). Oropharynx cancers that are positive for p16 expression are considered to be HPV-related. HPV-related (p16-positive) oropharynx cancer is usually considered less aggressive than oropharynx cancer that is unrelated to HPV or other cancers that are located in the larynx and hypopharynx.

Where’s this trial being run?

University Hospital Galway

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	NRG HN009
Number:	22-04
Full Title:	NRG HN009: Randomised Phase II/III Trial Of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 For Patients With Locoregionally Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN).

Principal Investigator:	Prof Sinead Brennan
Type:	Collaborative
Sponsor:	NRG Oncology
Recruitment Started:	Global: Ireland:

Global Recruitment Target:	464
Ireland Recruitment Target:	105